---------------------------
		      *  Welcome to R.E.D. III  *
		         RESP ESP charge Derive  
		  http://q4md-forcefieldtools.org/RED/ 

		         CHARGE TYPE = RESP-A1
		      ---------------------------

  ==========================================================================  
  ====================      Single molecule     ============================  
	 The molecule TITLE is "Dimethylalanine-dipeptide"
		The TOTAL CHARGE value of the molecule is "0"
	      The SPIN MULTIPLICITY value of the molecule is "1"
  ==========================================================================  

		    * Selected optimization output *
				GAMESS
		    Optimization OUTPUT looks nice ! 

		     * 1 conformation(s) selected *

			       WARNING:
		  A 2nd column of atom names is detected
        This 2nd column will be used in the PDB (& Tripos) file(s)

			       WARNING:
	 No three atom based re-orientation found in the PDB file
     Re-orientation will be done according to the GAMESS Algorithm!

		        * Selected QM Software *
			        GAMESS 

		         * Software checking *
	   rungms 							[ OK ]
	   gamess.00.x 							[ OK ]
	   ddikick.x 							[ OK ]
	   resp 							[ OK ]

   MEP(s) is/are being computed for molecule 1 ...			[ OK ]
	See the file(s) "JOB2-gam_m1-1-(X).log"

   The RESP-A1 charges are being derived for molecule 1 ...		[ OK ]
	See the "punch2_m1" file(s)

	The following Tripos Mol2 file(s) has/have been created.
	Mol_m1-o1.mol2


	Execution time: 0 h 15 m 18 s

  ***********************************************************************
    R.E.D. I was developed at the "Faculte de Pharmacie" in Amiens
         by:  A. Pigache (1), P. Cieplak (2) & F.-Y. Dupradeau (1)

    R.E.D. II was developed in Prof. D.A. Case's laboratory
         by:  T. Zaffran (1,3), P. Cieplak (2) & F.-Y. Dupradeau (1,3)

    R.E.D. III development was initiated in Prof. D.A. Case's laboratory
            & finalized at the "Faculte de Pharmacie" in Amiens
         by:  N. Grivel (1,3), P. Cieplak (4) & F.-Y. Dupradeau (1,3)

    R.E.D. IV is now developed at the "Faculte de Pharmacie" in Amiens

     (1) DMAG EA 3901, Faculte de Pharmacie, Amiens, France
     (2) Accelrys Inc., San Diego, USA
     (3) The Scripps Research Institute, La Jolla, CA, USA
     (4) Burnham Institute for Medical Research, La Jolla, CA, USA
   ***********************************************************************